Xilio Therapeutics, Inc. (XLO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XLO SEC filings page.
Xilio Therapeutics, Inc. (XLO) reported $64.1M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Xilio remains a development-stage business: new revenue sharply reduced cash use, but research spending and leverage still shape the model.
From FY2024 to FY2025, reported revenue rose from$6.3M to$43.8M . That top-line step coincided with operating cash flow improving from-$18.4M to-$5.0M , indicating the cash improvement was tied to reported business receipts rather than simply reduced spending.
Research and development spending was
Total liabilities reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Xilio Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xilio Therapeutics, Inc. held $137.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $5.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Xilio Therapeutics, Inc. scores 99/100 among other emerging companies.
Xilio Therapeutics, Inc. had 6M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Xilio Therapeutics, Inc. scores 90/100 among other emerging companies.
Xilio Therapeutics, Inc. spent $56.0M on research and development in fiscal year 2025, which was 65.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Xilio Therapeutics, Inc. scores 87/100 among other emerging companies.
Xilio Therapeutics, Inc. reported revenue of $43.8M in fiscal year 2025, against $6.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Xilio Therapeutics, Inc. scores 97/100 among other emerging companies.
Xilio Therapeutics, Inc.'s operations used $5.0M of cash in fiscal year 2025, against $18.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Xilio Therapeutics, Inc. scores 86/100 among other emerging companies.
Xilio Therapeutics, Inc.'s cash, cash equivalents and investments came to $137.5M at the end of fiscal year 2025, against $119.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Xilio Therapeutics, Inc. scores 62/100 among other emerging companies.
Xilio Therapeutics, Inc. scores -3.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($59.6M) relative to total liabilities ($119.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Xilio Therapeutics, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Xilio Therapeutics, Inc. reported a net loss of $35.0M while operations used $5.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Xilio Therapeutics, Inc. generated $18.7M in revenue in Q2 2026. This represents an increase of 131.2% from the same quarter a year earlier. Against the prior quarter it is up 47.8%.
Xilio Therapeutics, Inc.'s EBITDA was -$3.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 77.2% from the same quarter a year earlier. Against the prior quarter it is up 76.8%.
Xilio Therapeutics, Inc. reported -$6.4M in net income in Q2 2026. This represents an increase of 59.8% from the same quarter a year earlier. Against the prior quarter it is up 33.1%.
Xilio Therapeutics, Inc. earned -$0.33 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 43.1%.
Cash & Balance Sheet
Xilio Therapeutics, Inc. recorded an outflow of $18.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 26.2% from the same quarter a year earlier. Against the prior quarter it is up 18.0%.
Xilio Therapeutics, Inc. held $136.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Xilio Therapeutics, Inc.'s operating margin was -18.7% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Xilio Therapeutics, Inc.'s net profit margin was -34.1% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 41.3 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Xilio Therapeutics, Inc.'s ROE was -8.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 215.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.3 percentage points.
Not reported for Q2 2026.
Capital Allocation
Xilio Therapeutics, Inc. invested $14.6M in research and development in Q2 2026. This represents a decrease of 5.0% from the same quarter a year earlier. Against the prior quarter it is down 26.6%.
Xilio Therapeutics, Inc. invested $19K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 95.3% from the same quarter a year earlier. Against the prior quarter it is down 96.6%.
Not reported for Q2 2026.
XLO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M+131.2% | $12.6M+331.7% | $13.7M | $19.1M+742.5% | $8.1M+243.0% | $2.9M | N/A | $2.3M |
| R&D Expenses | $14.6M-5.0% | $19.8M+139.9% | $18.1M | $14.3M+33.1% | $15.3M+36.7% | $8.3M-20.5% | N/A | $10.8M-2.6% |
| SG&A Expenses | $7.6M+7.1% | $6.9M-18.6% | $7.4M | $6.7M+5.8% | $7.1M+22.4% | $8.5M+38.7% | N/A | $6.3M0.0% |
| Operating Income | -$3.5M+75.7% | -$14.1M-1.9% | -$11.8M | -$1.9M+86.9% | -$14.4M+2.3% | -$13.9M+20.8% | N/A | -$14.8M+15.0% |
| EBITDA | -$3.2M+77.2% | -$13.8M-3.1% | -$11.5M | -$1.6M+88.7% | -$14.0M+2.1% | -$13.4M+21.6% | N/A | -$14.4M+15.0% |
| Net Income | -$6.4M+59.8% | -$9.5M+28.2% | $10.4M | -$16.3M-16.2% | -$15.8M-13.8% | -$13.3M+22.9% | N/A | -$14.0M+16.3% |
| EPS (Basic) | -$0.33+85.7% | -$0.58+76.7% | -$3.76-1988.9% | -$0.11+50.0% | -$2.30-858.3% | -$2.49-301.6% | -$0.18+71.9% | -$0.22+63.9% |
| EPS (Diluted) | -$0.33 | -$0.58 | -$3.76 | -$0.11 | -$2.30 | -$2.49 | -$0.18+71.9% | -$0.22 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax, Diluted Shares (Avg).
XLO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $154.3M+15.3% | $163.5M+57.6% | $154.7M+117.6% | $133.7M+79.1% | $133.8M+48.9% | $103.7M+25.6% | $71.1M+16.7% | $74.7M-4.1% |
| Current Assets | $145.5M+17.6% | $154.2M+65.5% | $145.0M+140.8% | $124.1M+96.0% | $123.7M+58.6% | $93.2M+34.7% | $60.2M+25.2% | $63.3M-1.8% |
| Cash & Equivalents | $136.0M+11.9% | $150.3M+68.8% | $137.5M+148.7% | $103.8M+69.4% | $121.6M+62.2% | $89.1M+162.1% | $55.3M+23.7% | $61.3M+2.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $82.0M-35.3% | $90.9M-2.2% | $119.4M+123.3% | $141.8M+164.1% | $126.7M+124.5% | $93.0M+63.6% | $53.5M+121.9% | $53.7M+111.8% |
| Current Liabilities | $34.2M-35.8% | $43.0M-9.8% | $56.3M+106.4% | $56.4M+48.3% | $53.3M+37.8% | $47.6M+50.8% | $27.3M+70.8% | $38.0M+124.6% |
| Non-Current Liabilities | $47.8M-35.0% | $48.0M+5.7% | $63.1M+140.8% | $85.4M+445.2% | $73.5M+312.5% | $45.4M+79.6% | $26.2M+222.0% | $15.7M+86.1% |
| Total Equity | $72.3M+922.3% | $72.5M+578.0% | $35.3M+100.4% | -$8.1M-138.6% | $7.1M-78.8% | $10.7M-58.5% | $17.6M-52.2% | $21.0M-60.0% |
| Retained Earnings | -$434.7M-5.3% | -$428.3M-7.9% | -$418.8M-9.1% | -$429.1M-15.8% | -$412.9M-15.8% | -$397.0M-15.8% | -$383.8M-17.9% | -$370.7M-20.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
XLO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.8M-29.6% | -$22.3M-177.1% | -$2.0M+85.9% | -$17.5M-28.0% | -$14.5M-172.6% | $29.0M+375.9% | -$14.2M-5.4% | -$13.7M-2.3% |
| Depreciation & Amortization | $300K-25.0% | $344K-30.8% | $323K-14.1% | $300K-25.0% | $400K-10.1% | $497K+12.2% | $376K-16.3% | $400K-13.0% |
| Stock-Based Compensation | $1.6M+18.3% | $2.2M+44.0% | N/A | $1.1M-28.7% | $1.4M-10.6% | $1.5M-16.3% | N/A | $1.6M-15.4% |
| Capital Expenditures | $19K-95.3% | $556K+2427.3% | $95K+1483.3% | $0-100.0% | $401K | $22K | $6K | $9K |
| Free Cash Flow | -$18.8M-26.2% | -$22.9M-179.1% | -$2.1M+85.2% | -$17.5M-27.9% | -$14.9M | $29.0M | -$14.2M-5.5% | -$13.7M-2.3% |
| Investing Cash Flow | -$19K+95.3% | -$556K-2427.3% | -$95K-1483.3% | $0+100.0% | -$401K | -$22K | -$6K | -$9K |
| Financing Cash Flow | $4.5M-90.5% | $35.7M+639.0% | $35.9M+337.3% | -$285K-9400.0% | $47.4M+136.3% | $4.8M+406.5% | $8.2M+602.0% | -$3K+99.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
XLO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18.7% | -111.6% | -86.5% | -10.1% | -177.7% | -472.7% | N/A | -652.3% |
| Net Margin | -34.1% | -75.3% | 75.7% | -85.4% | -196.0% | -452.7% | N/A | -619.5% |
| Return on Equity | -8.8%+215.3pp | -13.1%+110.8pp | 29.4% | N/A | -224.1%-182.5pp | -124.0%-57.2pp | N/A | -66.8%-34.9pp |
| Return on Assets | -4.1%+7.7pp | -5.8%+7.0pp | 6.7% | -12.2%+6.6pp | -11.8%+3.7pp | -12.8%+8.0pp | N/A | -18.8%+2.7pp |
| Current Ratio | 4.25+1.9x | 3.59+1.6x | 2.58+0.4x | 2.20+0.5x | 2.32+0.3x | 1.96-0.2x | 2.21-0.8x | 1.67-2.1x |
| Debt-to-Equity | 1.13-16.8x | 1.25-7.4x | 3.39+0.3x | N/A | 17.93+16.2x | 8.69+6.5x | 3.04+2.4x | 2.56+2.1x |
| Asset Turnover | 0.12+0.1x | 0.080.0x | 0.09 | 0.14+0.1x | 0.060.0x | 0.03 | N/A | 0.03 |
| FCF Margin | -100.5% | -181.1% | -15.3% | -91.8% | -184.0% | 988.3% | N/A | -604.5% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. XLO | FY2025 | $43.8M | -$35.0M | -80.0% | $59.6M | 87/100 |
| Mersana Therapeutics, Inc. MRSN | FY2024 | $40.5M | -$69.2M | N/A | $145.4M | 54/100 |
| LAVA Therapeutics N.V. LVTX | FY2024 | $12.0M | -$25.1M | N/A | $45.8M | 53/100 |
| Mural Oncology plc MURA | FY2024 | N/A | -$128.5M | N/A | $35.4M | — |
| BIOATLA INC BCAB | FY2025 | N/A | $59.6M | N/A | $2.9M | — |
| Jasper Therapeutics, Inc. JSPR | FY2025 | N/A | -$76 | N/A | $19.0M | — |
Where Xilio Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Xilio Therapeutics, Inc.'s annual revenue?
Xilio Therapeutics, Inc. (XLO) reported $43.8M in total revenue for fiscal year 2025. This represents a 589.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Xilio Therapeutics, Inc.'s revenue growing?
Xilio Therapeutics, Inc. (XLO) revenue grew by 589.9% year-over-year, from $6.3M to $43.8M in fiscal year 2025.
Is Xilio Therapeutics, Inc. profitable?
No, Xilio Therapeutics, Inc. (XLO) reported a net income of -$35.0M in fiscal year 2025, with a net profit margin of -80.0%.
What is Xilio Therapeutics, Inc.'s EBITDA?
Xilio Therapeutics, Inc. (XLO) had EBITDA of -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Xilio Therapeutics, Inc.'s operating margin?
Xilio Therapeutics, Inc. (XLO) had an operating margin of -95.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Xilio Therapeutics, Inc.'s net profit margin?
Xilio Therapeutics, Inc. (XLO) had a net profit margin of -80.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Xilio Therapeutics, Inc.'s return on equity (ROE)?
Xilio Therapeutics, Inc. (XLO) has a return on equity of -99.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xilio Therapeutics, Inc.'s free cash flow?
Xilio Therapeutics, Inc. (XLO) recorded an outflow of $5.5M in free cash flow during fiscal year 2025. This represents a 70.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Xilio Therapeutics, Inc.'s operating cash flow?
Xilio Therapeutics, Inc. (XLO) recorded an outflow of $5.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Xilio Therapeutics, Inc.'s total assets?
Xilio Therapeutics, Inc. (XLO) had $154.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Xilio Therapeutics, Inc.'s capital expenditures?
Xilio Therapeutics, Inc. (XLO) invested $518K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Xilio Therapeutics, Inc. spend on research and development?
Xilio Therapeutics, Inc. (XLO) invested $56.0M in research and development during fiscal year 2025.
What is Xilio Therapeutics, Inc.'s current ratio?
Xilio Therapeutics, Inc. (XLO) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.
What is Xilio Therapeutics, Inc.'s debt-to-equity ratio?
Xilio Therapeutics, Inc. (XLO) had a debt-to-equity ratio of 3.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xilio Therapeutics, Inc.'s return on assets (ROA)?
Xilio Therapeutics, Inc. (XLO) had a return on assets of -22.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xilio Therapeutics, Inc.'s P/E ratio?
Xilio Therapeutics, Inc. (XLO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $59.6M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Xilio Therapeutics, Inc.'s price-to-sales ratio?
Xilio Therapeutics, Inc. (XLO) trades at 0.9x sales, its market capitalization divided by revenue of $64.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $59.6M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Xilio Therapeutics, Inc.'s Altman Z-Score?
Xilio Therapeutics, Inc. (XLO) has an Altman Z-Score of -3.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Xilio Therapeutics, Inc.'s Piotroski F-Score?
Xilio Therapeutics, Inc. (XLO) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xilio Therapeutics, Inc.'s earnings high quality?
Xilio Therapeutics, Inc. (XLO) reported a net loss of $35.0M while operations used $5.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. (XLO) scores 87 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.